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Abstract Pulmonary hypertension (PH) is an increasingly
recognized complication of systemic lupus erythematosus
(SLE). To develop a more comprehensive understanding of
the clinical and pathological characteristics of pulmonary
hypertension associated with systemic lupus erythematosus
(PH/SLE) in the Chinese population, a systematic review of
the literature up to 2012 was conducted. Six hundred and
forty-two Chinese PH/SLE cases from 22 studies were
identified as well documented and further analyzed. Trans-
thoracic echocardiography (TTE), X-ray, electrocardiogram
and right heart catheterization (RHC) were performed to
diagnose PH in SLE patients. The mean age of subjects was
35.5 years, the male to female ratio was 1:14, and the mean
duration of SLE when PH was diagnosed was 10.7 years.
The prevalence of PH in SLE was 2.8–23.3 %. Symptoms
were usually nonspecific, and the observed clinical charac-
teristics include Raynaud’s phenomenon (41.4 %), serous
effusion (27.7 %), positive RNP (51.5 %) and positive
ACL (46.6 %). Gold standard RHC is strongly recom-
mended, especially for those who had resting pulmonary
arterial systolic pressure [30 mmHg on TTE with the
aforementioned clinical characteristics. Corticosteroids,
immunosuppressants and vasodilators were the most com-
mon medications employed in treatment. Early identification
and standard PH treatment with intensive SLE treatment can
improve the prognosis.
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Introduction
Pulmonary hypertension (PH) is a severe, potentially life-
threatening complication of systemic lupus erythematosus
(SLE) [1, 2]. The reported prevalence of PH in SLE ranged
from 0.5 to 14 % in a previous review of the literature [3].
The mechanisms involved in the pathogenesis of PH are
largely unknown. Elevated antiendothelial cell antibodies
(aECA) were detected and reported in patients with SLE,
especially with PH, which implied that aECA may be
involved in the pathogenesis of vascular injury [4]. The
association of PH with SLE suggests an underlying
inflammatory component in the pathogenesis of this syn-
drome [5].
In SLE, the prognosis of patients with PH has been
reported to be very poor and the mean survival from the onset
of PH was 2 years [6–9]. PH is the third most common cause
of death in SLE following infection and organ failure [10].
With the widespread availability of high-quality imaging
systems and a better understanding of PH pathology [11, 12],
the number of such patients reported in the Chinese literature
has been steadily increasing. To better understand PH in SLE
and to raise more awareness and help clinicians, a systematic
review of the literature up to 2012 was conducted; clinical
and pathological characteristics of PH associated with SLE
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were examined; well-documented Chinese cases were
identified and further analyzed with the aim to provide a
more comprehensive understanding of PH in SLE in the
Chinese population.
Methods and materials
A comprehensive literature search was conducted to
retrieve up-to-date PH in SLE-related information up to
2012 from multiple sources including the Chinese Biology
and Medicine Database (CBMD), China Hospital Knowledge
Database (CHKD), Wanfang Database, VIP Information
Database, PubMed, Embase, Web of Science and Ovid.
Indexing keywords used for the search and retrieval
included PH, PAH, PHT, secondary pulmonary hyperten-
sion, primary pulmonary hypertension, lupus and systemic
lupus erythematosus.
With a clear focus on PH in SLE in the Chinese popu-
lation, all retrieved articles were carefully reviewed and
checked for possible duplication to avoid the repetitive
adoption of the same data and materials. The inclusion
criteria were made that SLE diagnosis has to meet at least
the 1982 revised ACR criteria of SLE [13] and diagnosis of
PH was made when the resting pulmonary arterial systolic
pressure (PASP) was [30 mmHg at rest by TTE (trans-
thoracic echocardiography). Excluded were other forms of
PH due to left heart disease, chronic lung disease and/or
hypoxemia, chronic thromboembolism and a miscellaneous
group as well as PH associated with other autoimmune
diseases (such as systemic sclerosis, mixed connective
tissue disease and so on).
All unduplicated cases meeting the above inclusion and
exclusion criteria were entered into a database. Cases were
considered well documented if they have at least 5 of the
following 7 categories of information: age, gender, symp-
toms, imaging, laboratory tests, treatment data (from the
clinical records) and follow-up. A total of 22 studies with
642 well-documented PH–SLE cases were included and
analyzed. All statistical analyses were performed using
SPSS 11.0 for Windows.
Results
Twenty-two studies with 642 well-documented PH–SLE
cases were included in this analysis. Thirteen studies
(59.1 %) were from Beijing, Shanghai and Guangzhou (the
capital of Guangdong province, adjacent to Hong Kong).
A sum of 430 patients came from these three cities,
representing two-thirds (67 %) of the total 642 cases.
Information about patients meeting the well-documented
SLE–PH criteria is listed in Table 1.
Of the 642 patients, 42 were males and 600 were
females. The male to female ratio was 1:14. Their age
ranged from 8 to 85 years (with a mean age of 35.5), and
their disease duration ranged from 0.5 to 50.5 years (with a
mean of 10.7 years). The prevalence rate of PH in SLE
reported in 12 studies ranged from 2.8 to 23.3 %.
The symptoms were usually nonspecific, and often
coexisted with several clinical characteristics. The three
most commonly observed were Raynaud’s phenomenon,
arthritis and serous effusion (Table 2).
One hundred and ninety-three patients (41.4 %) from 17
studies had Raynaud’s phenomenon. In seven studies,
51.2 % (32.4–77.8 %) of lupus patients with PH had
Raynaud’s phenomenon versus 19.9 % (10.3–36 %) of
Table 1 Patients meeting the well-documented SLE–PAH criteria
Criteria n %




Laboratory tests 532 82.9
Treatment 273 42.5
Follow-up 266 41.4
Total n = 642
Table 2 Symptoms of PAH associated with SLE patients (n = 466)
Symptoms Patients (n) %
Raynaud’s phenomenon 193 41.4
Arthritis 178 38.2
Serous effusion 129 27.7
Serositis 101 21.7




Acra vasculitis 37 7.9
Fever 29 6.2
Oral ulcer 24 5.2
Alopecie 20 4.3
Chest distress 16 3.4
P2 accentuation 15 3.2
Butterfly erythema 12 2.6
Photosensitivity 11 2.4
Palpitation 10 2.1
Dry mouth and eye 9 1.9
Limbs edema 9 1.9
Dyspnea 6 1.3
Myosalgia 5 1.1
1212 Rheumatol Int (2013) 33:1211–1217
123
lupus patients without PH. They reported correlation of
Raynaud’s phenomenon with PH.
One hundred and seventy-eight patients (38.2 %) from
12 studies had arthritis, mostly proximal interphalangeal
arthritis. Lupus is sometimes misdiagnosed as rheumatoid
arthritis because arthritis may precede other system
damages.
One hundred and twenty-nine patients (27.7 %) from
eight studies had serous effusion—primarily pericardial
effusion (88) and pleural effusion (10). In four studies,
57.3 % (44.4–63.9 %) of lupus patients with PH had serous
effusion versus 21.7 % (15.2–25 %) of lupus patients
without PH. They reported correlation of serous effusion
with PH.
One hundred and one patients (21.7 %) from six studies
had serositis. In four studies, 60.5 % (53.7–64.9 %) of
lupus patients with PH had serositis versus 29 %
(25.6–32.9 %) of lupus patients without PH. They reported
correlation of serositis with PH.
TTE, electrocardiography, chest X-ray and right heart
catheterization (RHC) were performed for the purpose of
diagnosing PH in lupus patients. The pulmonary artery
pressures of all 642 patients were measured by TTE. Two
studies compared the sensitivity of TTE with chest X-ray
and electrocardiography and reported the detection rates as
93.3, 26.7 and 26.7 %, respectively.
Among all the laboratory findings, positive ANA,
positive ACL and positive RNP were significantly higher in
the lupus patients with PH. As seen in Table 3, the anti-
ACL antibody in 198 patients (46.6 %) from 14 studies
was positive. In five studies, 51.3 % (46.2–56.8 %) of
lupus patients with PH had positive anti-ACL antibody
versus 23.8 % (16–28.9 %) of lupus patients without PH.
They all reported positive correlation of the presence of
anti-ACL antibody with the diagnosis of PH on TTE.
The anti-RNP antibody in 172 patients (51.5 %) from
twelve studies was positive. In five studies, 49.2 %
(13–80.5 %) of lupus patients with PH had positive anti-
RNP antibody versus 20 % (3.8–37.7 %) of lupus patients
without PH. They all reported positive correlation of the
presence of anti-RNP antibody with the diagnosis of PH on
TTE.
The anti-b2-GPI antibody in 72 patients (25 %) from
one study was positive; 25 % of lupus patients with PH had
positive anti-b2-GPI antibody versus 12 % of lupus
patients without PH. And it reported positive correlation of
the presence of anti-b2-GPI antibody with the diagnosis of
PH on TTE.
Corticosteroids, immunosuppressants, vasodilators and
anticoagulants were the commonly used medications for
the patients in this analysis (Table 4).
All 273 patients (42.5 %) from ten studies took two kinds
of corticosteroids as basic treatment—oral administration
(87.2 %) and intravenous injection (11 %). Cyclophospha-
mide was used in 156 patients (57.1 %) from the same ten
studies.
Two hundred and sixty-six patients (41.4 %) from nine
studies were followed up for 0.75–12 years (with a mean of
3.8 years). Forty-one of them (15.4 %) with PH died dur-
ing the follow-up period. Only six studies reported the
causes of death, which included right heart failure, kidney
failure, severe infection, pulmonary embolism, cardiac
arrest, arrhythmia, alimentary tract hemorrhage, cerebral
vascular accident and sudden death. One hundred and
thirteen patients (42.5 %) showed 23.8 % (4.5–73.3 %)
Table 3 Auto-antibodies of SLE patients with PAH
Auto-antibodies Patients Positivity, n (%)
ANA (?) 230 222 (96.5)
Ds-DNA (?) 283 167 (59.0)
RNP (?) 334 172 (51.5)
SSA (?) 271 127 (46.9)
ACL (?) 425 198 (46.6)
Rib (?) 9 3 (33.3)
Antithrombase (?) 72 24 (33.3)
SSB (?) 245 73 (29.8)
Antiplasmin (?) 72 21 (29.2)
Sm (?) 257 68 (26.5)
b2-GPI (?) 72 18 (25.0)
AHA (?) 62 15 (24.2)
ANCA (?) 139 18 (12.9)
Scl-70 (?) 47 6 (12.8)
Anti-APC (?) 72 8 (11.1)
Jo-1 (?) 15 1 (6.7)
T-PA (?) 72 3 (4.2)
ANA anti-nuclear antibody, Anti-ds-DNA anti-double-stranded DNA,
RNP anti-ribonucleoprotein antibody, SSA anti-Sjogren syndrome A
antibody, ACL anti-cardiolipin antibody, Rib anti-ribosome antibody,
SSB anti-Sjogren syndrome B antibody, Sm anti-Smith antigen,
b2-GPI anti-cardiolipin-b2-glycoprotein I complex, AHA anti-histone
antibody, ANCA anti-neutrophil cytoplasmic antibody, Scl-70
anti-topoisomerase 1 antibody, APC anti-activated protein C antibody,
Jo-1 anti-histidyl-tRNA synthetase antibody, T-PA anti-tissue-type
plasminogen activator antibody






Other medicines 23 8.4
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improvement of their right ventricular systolic pressure by
Doppler echocardiography after appropriate drug inter-
vention. Sixty-eight patients (25.6 %) showed 11.6 %
(1.8–61.7 %) aggravation of PH after treatment.
Discussion
Pulmonary hypertension (PH) has been reported in almost
all rheumatic diseases including systemic sclerosis and
SLE [14–17]. It is an increasingly recognized manifestation
of SLE and an important reason for morbidity and mor-
tality [18, 19]. SLE with PH attracts more and more clinical
and academic attentions.
It takes time for SLE–PH to be recognized and reported.
In 1954, Harvey et al. [20] reported no PH in 138 SLE
patients. In 1981, Perez and Kramer reported a 9 % prev-
alence rate of PH in SLE patients [21]. The reported PH
prevalence rates varied greatly depending on the type of
study. Retrospective studies reported prevalence rates of
0.5–6 % [19], while prospective studies in asymptomatic
patients found higher prevalence rates of 9–14 % [6, 22].
In this analysis, we found the prevalence rate of SLE–PAH
in China ranged from 2.8 to 23.3 % as reported by twelve
retrospective studies. The wide variability in the reported
prevalence rates reflects the varying definitions of PH,
differences in diagnostic methods, population groups
studied and number of patients involved [23]. The preva-
lence rate from prospective cross-sectional cohort study
would be better than the retrospective smaller studies, but
no reports were found yet.
It is noteworthy that more than half of patients in this
analysis originated from the three big metropolitan cities
(Beijing, Shanghai and Guangzhou) in China. This may not
necessarily indicate that the prevalence of SLE–PH in the
three places was higher than the rest of China. It may
simply be that these cities have more medical resources and
expertise in recognizing and diagnosing PH and patients
there can better afford the costs of medical care.
The pathogenesis of PH in SLE is not well understood.
Abnormal vasospasm, Raynaud’s phenomenon, platelet
abnormalities, vasculitis, thrombosis and thromboembo-
lism have been suggested as possible pathogenetic factors
[8, 24, 25]. Endothelial dysfunction is strongly implicated
in the pathogenesis of autoimmune vasculitic diseases
including lupus [26, 27]. Nakamura et al. [28] found the
elevation of endothelin may be associated with PH and
possibly related to disease activity in a murine lupus
model. Shen et al. [29] reported that PH patients had higher
serum endothelin more commonly in the active stage and
the level of endothelin was correlated with pulmonary
pressure. In addition, a variety of auto-antibodies in vivo of
lupus patients can cause vascular endothelial cell injury
such as ACL, LA, ANA, ds-DNA. They could directly
damage the endothelial cells or form immune complexes
and then deposit in the vascular wall, leading to vasocon-
striction, platelet aggregation and the formation of throm-
bosis. In our study, we found that positive ACL and
positive RNP were correlated with PH and they were
strong predictors of PH in some studies, which are com-
patible with previous findings [30–32]. Only one study
reported 25 % anti-b2-GPI antibody was positive in 72
SLE–PH patients, which is consistent with Houman’s
research studied in Tunisia (25 % of positive for anti-
b2-GPI in 100 patients) [33].
Most cases of SLE-associated PH are mild, which makes
early diagnosis difficult, and only those cases presenting
with severe PH have been reported. Lian et al. [30] sug-
gested that more than 40 % of the SLE–PH patients would
not have observable symptoms when early PH persisted. In
general, the clinical symptoms of SLE patients with PH are
nonspecific such as progressively exertional dyspnea, chest
pain, nonproductive cough, edema, easy fatigue, impaired
exercise tolerance [14], and can also be caused by many
other factors including pleural or pericardial effusions,
interstitial lung disease, making it possible to miss the
diagnosis [34]. Physical findings include a loud second
pulmonic heart sound, pedal edema, serous effusion,
Raynaud’s phenomenon and so on. In this study, the non-
specific symptoms reported above were not so common as
Raynaud’s phenomenon and serous effusion. One hundred
and ninety-three patients (41.4 %) presented Raynaud’s
phenomenon. Raynaud’s phenomenon is characterized by
vasospasm and could be the cutaneous manifestation of
general vascular disorder resulting in pulmonary arterial
vasoconstriction [3, 35]. The high frequency of Raynaud’s
phenomenon patients with SLE and PH suggests a potential
role for etiology of PH, and also supports the notion that
Raynaud’s phenomenon is a pathogenic risk factor and a
marker for disease severity [30, 36].
TTE has been widely used to screen for PH due to its
safety, convenience and sensitivity. Denton et al. [37]
reported that TTE had a sensitivity of 90 % and a speci-
ficity of 75 % compared with RHC. Gonzalez et al. [38]
compared TTE with RHC to detect PH and found that the
method of applying differential pressure of tricuspid
regurgitation for estimating pulmonary hypertension had
high accuracy with a sensitivity of 83.3–90 % and a
specificity of 75 %. RHC is considered the gold standard
test in the diagnosis and classification of PH. PH may be
caused by venous or arterial changes, and pulmonary vas-
culitis in SLE patients can lead to pulmonary arterial
hypertension (PAH). RHC is currently the only way to
differentiate what kind of PH that SLE patients suffered
from. Besides, with an assessment of vasoreactivity, RHC
is necessary if PH is highly suspected and is needed for
1214 Rheumatol Int (2013) 33:1211–1217
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decision making with particular respect to treatment. Jais
et al. [39] emphasized that RHC was mandatory before
starting any treatment and for following-up PAH patients
and showed it provided strong predictors of response to
immunosuppressive therapy by reliably measuring cardiac
index and calculating pulmonary vascular resistance.
Insidious onset of SLE-associated PH develops rapidly.
It is irreversible and usually of poor outcome with a 2- to
5-year survival after initial diagnosis [40]. Therefore, early,
intensive treatment for the primary disease (SLE) is the key
to improve prognosis. Various drugs have been used for the
treatment of SLE-associated PH, such as corticosteroids,
immunosuppressants, vasodilators, endothelin receptor
antagonists and anticoagulants. They could improve the
symptoms of lupus, and only some of them had an effect on
decreasing the pulmonary artery pressure. But there was a
lack of detailed comparison of the results of different
combined therapies. Corticosteroids plus immunosuppres-
sants can block the immune-mediated vascular inflamma-
tion in the early stage. Promising results have been
obtained with combination therapy that includes steroids
and cyclophosphamide in patients with early stages of PH
[22]. Abnormal pulmonary and cardiac function can be
improved by immunosuppressants and corticosteroids
alone or combined with pulmonary vasodilators [39]. If a
patient is strongly vasodilator responsive, then treatment
with high dosage of calcium channel blocker should be
adequate [34]. It has been proved that traditional vasodi-
lators could improve hemodynamics, increase exercise
tolerance and prolong survival time by reducing right
ventricular afterload. However, there are potential unde-
sirable response such as an increase in ventilation/perfu-
sion mismatch and a reduction in systemic vascular
resistance, leading to hypotension [20, 41]. If a patient is
not vasodilator responsive, then treatment would include
endothelin receptor blockers [34]. There are two kinds of
endothelin receptor blockers: selective and nonselective.
Bosentan, a nonselective endothelin receptor blocker, was
reported by Ahmadi-Simab et al. [42] to have a good effect
on relieving PH. Mok et al. [43] found 12 months of bos-
entan treatment resulted in significant improvement in six-
minute walk distance (6MWD), transient or sustained drop
in systolic PAP. Because of endothelial dysfunction in
lupus patients with PH, long-term hypoxia and hypercapnia
lead to secondary polycythemia, hypercoagulability, stasis
of the microcirculation, and then increasing risk of
thrombosis and embolism. Thus, anticoagulant therapy has
been recommended to be used with other medicines such as
corticosteroids and immunosuppressants. However, the
effect of warfarin anticoagulation is controversial for the
treatment of idiopathic PAH patients, and there is no evi-
dence to support that anticoagulant therapy provides ben-
efit for SLE–PAH patients.
Some Chinese herbals may also relieve PH. Tang et al.
[44] found ligustrazine extracted from ligustici could
decrease the level of endothelin through inhibiting the
expression and release of ET-1 in hypoxic PH rats. Jiang
et al. [45] observed salvia miltiorrhiza may depress the
secretion of endothelin and then reduce hypoxic pulmonary
vasoconstriction. Gene therapies for PH have been suc-
cessful in the laboratory with the potential for effective
treatments. Lung transplantation is the only measure to
treat advanced PH, and 1-year survival rate after trans-
plantation is 65–70 %.
In general, the prognosis in mild and moderate disease is
not certain, depends on different therapies and courses of
treatment. However, SLE patients with severe symptomatic
PH carry a poor prognosis. Oren et al. [46] reported the
overall 2-year survival was B50 % when pulmonary
hypertension was present. Chung et al. [47] reported PH in
SLE untreated had a 3-year mortality of 54.1 %. In recent
years, SLE patients have improved survival rate closer to
idiopathic PAH with the advent of PAH-specific therapies
[48, 49].
A major limitation of this study is that RHC confirma-
tion of PH was not performed on all patients.
PASP [ 30 mmHg on TTE in lupus patients was chosen
a priori, and there are concerns about TTE’s sensitivity and
specificity. In addition, most studies were retrospective
with small sample sizes. Therefore, multi-center prospec-
tive cohort studies of SLE patients with PH are called for in
China.
In conclusion, PH is an increasingly recognized com-
plication in SLE. PH associated with SLE typically affects
middle-age women and is often characterized by nonspe-
cific symptoms and poor prognosis. Early diagnosis is
essential for SLE patients with PH. Gold standard RHC is
strongly recommended since symptoms of PH in lupus
patients are nonspecific, especially for those who had
PASP [ 30 mmHg on TTE with positive anti-ACL or anti-
RNP antibodies or Raynaud’s phenomenon or serous
effusion or serositis. Early identification, standard PH
treatment as well as intensive treatment for SLE can
improve the prognosis.
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